NCT06578637View on ClinicalTrials.gov

Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
FAPFamilial Adenomatous Polyposis
Interventions
DIETARY_SUPPLEMENT

R-1,3-Butanediol (10G-A)

Study participants will take one 35mL dose of HVMN Ketone-IQ by mouth per day (10 total grams of R-1,3-Butanediol) for 2 weeks

DIETARY_SUPPLEMENT

R-1,3-Butanediol (20G-A)

Study participants will take two 35mL dose of HVMN Ketone-IQ by mouth per day (20 total grams of R-1,3-Butanediol) for 2 weeks

DIETARY_SUPPLEMENT

R-1,3-Butanediol (30G-A)

Study participants will take three 35mL dose of HVMN Ketone-IQ by mouth per day (30 total grams of R-1,3-Butanediol) for 2 weeks

DIETARY_SUPPLEMENT

R-1,3-Butanediol (30G-B)

Study participants will take one 35mL dose of HVMN Ketone-IQ by mouth three times per day (30 total grams of R-1,3-Butanediol) for 12 weeks, with a possible additional 12 week extension

Trial Locations (1)

19104

RECRUITING

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

The V Foundation for Cancer Research

OTHER

lead

Abramson Cancer Center at Penn Medicine

OTHER